[go: up one dir, main page]

EA201690048A1 - Способ и аппарат для фармакокинетической схемы дозирования лекарственного средства - Google Patents

Способ и аппарат для фармакокинетической схемы дозирования лекарственного средства

Info

Publication number
EA201690048A1
EA201690048A1 EA201690048A EA201690048A EA201690048A1 EA 201690048 A1 EA201690048 A1 EA 201690048A1 EA 201690048 A EA201690048 A EA 201690048A EA 201690048 A EA201690048 A EA 201690048A EA 201690048 A1 EA201690048 A1 EA 201690048A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dosing regimen
dosing
pharmacokinetic
plasma protein
patient
Prior art date
Application number
EA201690048A
Other languages
English (en)
Other versions
EA037962B1 (ru
Inventor
Александра Лев-Базелли
Джералд Дики Споттс
МиунгШин Ох
Original Assignee
Баксалта Инкорпорейтед
Баксалта Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52111779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690048(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Баксалта Инкорпорейтед, Баксалта Гмбх filed Critical Баксалта Инкорпорейтед
Publication of EA201690048A1 publication Critical patent/EA201690048A1/ru
Publication of EA037962B1 publication Critical patent/EA037962B1/ru

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Primary Health Care (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Computing Systems (AREA)
  • Databases & Information Systems (AREA)
  • Physiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Probability & Statistics with Applications (AREA)

Abstract

Система и способ предоставления схемы дозирования терапевтического белка плазмы включают определение фармакокинетического профиля пациента с использованием байесовской модели фармакокинетических профилей пациентов, у которых брали образцы. Примерные система и способ также включают определение первой схемы дозирования для первого заданного интервала дозирования, которая содержит (i) первую дозу и (ii) первый уровень терапевтического белка плазмы у пациента в течение периода времени, на основании, по меньшей мере, фармакокинетического профиля, и определение второй схемы дозирования для второго заданного интервала дозирования, которая содержит (i) вторую дозу и (ii) второй уровень терапевтического белка плазмы у пациента в течение периода времени, на основании по меньшей мере фармакокинетического профиля. Примерные система и способ дополнительно включают отображение первой схемы дозирования и второй схемы дозирования на клиентском устройстве так, что первую схему дозирования отображают в сочетании со второй схемой дозирования.
EA201690048A 2013-06-20 2014-06-20 Способ и аппарат для фармакокинетической схемы дозирования лекарственного средства EA037962B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361837421P 2013-06-20 2013-06-20
US201361840969P 2013-06-28 2013-06-28
US201361881214P 2013-09-23 2013-09-23
PCT/US2014/043517 WO2015006033A1 (en) 2013-06-20 2014-06-20 Providing a pharmacokinetic drug dosing regime

Publications (2)

Publication Number Publication Date
EA201690048A1 true EA201690048A1 (ru) 2016-05-31
EA037962B1 EA037962B1 (ru) 2021-06-16

Family

ID=52111779

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690048A EA037962B1 (ru) 2013-06-20 2014-06-20 Способ и аппарат для фармакокинетической схемы дозирования лекарственного средства

Country Status (23)

Country Link
US (1) US20140379629A1 (ru)
EP (3) EP3879534A1 (ru)
JP (4) JP2016526542A (ru)
KR (4) KR102296042B1 (ru)
CN (2) CN105592973B (ru)
AU (3) AU2014287706B2 (ru)
BR (3) BR112015031856A8 (ru)
CA (1) CA2915472C (ru)
CL (1) CL2015003641A1 (ru)
EA (1) EA037962B1 (ru)
ES (1) ES2882832T3 (ru)
GE (2) GEP20186882B (ru)
IL (3) IL279313B (ru)
MX (3) MX373454B (ru)
MY (2) MY195911A (ru)
NZ (1) NZ715216A (ru)
PH (1) PH12015502800B1 (ru)
PL (1) PL3010681T3 (ru)
SA (2) SA521430246B1 (ru)
SG (1) SG11201510515YA (ru)
UA (1) UA118109C2 (ru)
WO (1) WO2015006033A1 (ru)
ZA (1) ZA201600100B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014014106A2 (pt) * 2011-12-13 2017-06-13 Koninklijke Philips Nv sistema, e método
WO2014055978A1 (en) 2012-10-05 2014-04-10 Baysient LLC System and method for providing patient-specific dosing as a function of mathematical models
WO2015085276A1 (en) * 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
WO2015154090A1 (en) 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
US11062797B2 (en) * 2014-10-10 2021-07-13 Continuous Precision Medicine Method and system for obtaining and using pharmacokinetic data in drug administration
EP4050616A1 (en) 2015-04-09 2022-08-31 Diane R. Mould Systems and methods for patient-specific dosing
WO2017136583A1 (en) * 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
KR102415992B1 (ko) * 2016-04-15 2022-07-04 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법을 제공하는 방법 및 장치
JP6807015B2 (ja) * 2016-06-13 2021-01-06 ソニー株式会社 情報処理装置、情報処理方法、およびプログラム
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2018144373A1 (en) * 2017-02-01 2018-08-09 Shire Human Genetic Therapies, Inc. A physiological sensing and therapeutic administration system and method
WO2020163441A1 (en) * 2019-02-06 2020-08-13 Optimdosing Llc Smart multidosing
BE1027052A1 (fr) 2019-02-14 2020-09-07 Aardex Group Procede d'assistance a la prise ou a l'acte d'un traitement therapeutique
US10970651B1 (en) * 2019-12-02 2021-04-06 Sas Institute Inc. Analytic system for two-stage interactive graphical model selection
KR102420872B1 (ko) * 2020-12-18 2022-07-14 포항공과대학교 산학협력단 강화학습과 약동-약력학 모델을 이용한 연속 약물 투여량 결정 방법
CN113053508B (zh) * 2021-03-29 2024-07-26 深圳市科曼医疗设备有限公司 基于触控屏的交互控制方法及装置

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07124125A (ja) * 1993-11-04 1995-05-16 S R L:Kk 薬物投与解析システム
SI0796623T1 (en) * 1996-03-20 2005-10-31 Baxter Aktiengesellschaft Pharmaceutical preparation for the treatment of blood coagulation disorders
AU5219798A (en) * 1996-12-09 1998-07-03 Samuel David Gpi-ceruloplasmin, analogs thereof, and methods of use
RU2248215C2 (ru) * 1999-05-11 2005-03-20 Орто-Макнейл Фармасьютикал, Инк. Фармакокинетическое и фармакодинамическое моделирование введения эритропоэтина
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
CA2419244A1 (en) * 2000-09-15 2002-03-21 Virco Bvba System and method for optimizing drug therapy for the treatment of diseases
NZ541475A (en) * 2003-02-01 2007-06-29 Baxter Int Wireless medical data communication system and method
EP1642607A1 (en) * 2004-10-04 2006-04-05 Sanofi-Aventis Deutschland GmbH Dose display mechanism for a drug delivery device
JP2006155071A (ja) * 2004-11-26 2006-06-15 Toshiba Sumiden Medical Information Systems Corp 電子カルテ薬物療法指示実施システム
US20060183786A1 (en) * 2005-02-16 2006-08-17 Chi Mei Foundation Hospital Injectable long-acting analgesic composition comprising an ester derivative of ketorolac
US8589175B2 (en) 2005-11-29 2013-11-19 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
WO2009120991A2 (en) * 2008-03-27 2009-10-01 Medtronic, Inc. Pharmacokinetic and pharmacodynamic tools to define patient specific therapeutic regimens
US8591454B2 (en) * 2008-11-10 2013-11-26 The Invention Science Fund I, Llc Administering a therapeutic agent with more than one taggant
US9050318B2 (en) * 2009-12-06 2015-06-09 Biogen Idec Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof

Also Published As

Publication number Publication date
JP2019196352A (ja) 2019-11-14
JP2022105022A (ja) 2022-07-12
IL243208A0 (en) 2016-02-29
KR102352133B1 (ko) 2022-01-18
BR122022000127A8 (pt) 2022-08-30
KR102397974B1 (ko) 2022-05-13
BR122020013811A8 (pt) 2022-08-30
IL243208B (en) 2020-06-30
AU2017272293A1 (en) 2018-01-04
BR112015031856A8 (pt) 2022-08-30
CN105592973B (zh) 2020-06-19
AU2017272293B2 (en) 2020-01-23
JP2016526542A (ja) 2016-09-05
GEP20186882B (en) 2018-07-25
AU2020202664A1 (en) 2020-05-14
EP3879534A1 (en) 2021-09-15
GEP20196990B (en) 2019-07-10
PH12015502800B1 (en) 2018-10-24
KR20210110736A (ko) 2021-09-08
IL279313B (en) 2022-08-01
AU2014287706A1 (en) 2016-01-21
NZ715216A (en) 2020-07-31
CL2015003641A1 (es) 2016-10-28
SA521430246B1 (ar) 2022-09-14
ES2882832T3 (es) 2021-12-02
MX2015017878A (es) 2016-09-14
IL274848A (en) 2020-07-30
SG11201510515YA (en) 2016-01-28
MX2023000359A (es) 2023-02-13
JP2021061012A (ja) 2021-04-15
CN111508557B (zh) 2024-03-26
EP3010681A1 (en) 2016-04-27
MY195911A (en) 2023-02-27
JP6813237B2 (ja) 2021-01-13
IL279313A (en) 2021-01-31
EA037962B1 (ru) 2021-06-16
CN105592973A (zh) 2016-05-18
KR20220011217A (ko) 2022-01-27
CA2915472C (en) 2023-09-19
JP7398031B2 (ja) 2023-12-14
BR122022000127A2 (ru) 2017-07-25
US20140379629A1 (en) 2014-12-25
KR20220065097A (ko) 2022-05-19
ZA201600100B (en) 2019-09-25
BR122020013811A2 (ru) 2017-07-25
JP7060291B2 (ja) 2022-04-26
EP3010681A4 (en) 2017-03-08
AU2014287706B2 (en) 2017-10-05
MY176173A (en) 2020-07-24
MX373454B (es) 2020-04-23
CA2915472A1 (en) 2015-01-15
KR102296042B1 (ko) 2021-08-31
EP3010681B1 (en) 2021-05-19
UA118109C2 (uk) 2018-11-26
BR112015031856A2 (pt) 2017-07-25
CN111508557A (zh) 2020-08-07
MX2020004112A (es) 2020-07-24
PH12015502800A1 (en) 2016-03-14
EP3309696A1 (en) 2018-04-18
AU2020202664B2 (en) 2022-06-02
PL3010681T3 (pl) 2021-11-15
WO2015006033A1 (en) 2015-01-15
SA515370289B1 (ar) 2022-02-02
KR20160022874A (ko) 2016-03-02

Similar Documents

Publication Publication Date Title
EA201690048A1 (ru) Способ и аппарат для фармакокинетической схемы дозирования лекарственного средства
MX2021011813A (es) Sistemas y metodos para compensar a largo plazo la sensibilidad de la deriva de sensores electroquimicos de gas expuestos a oxido nitrico.
EA201791206A1 (ru) Система и способ наблюдения ингаляции
MX2022012914A (es) Dispositivos y metodos para administracion y mezcla de farmaco, y entrenamiento de tecnicas apropiadas para ello.
SG10201806539XA (en) Liquid protein formulations containing ionic liquids
IN2015DN03826A (ru)
MX2018013503A (es) Aparatos, métodos y sistemas para administrar medicamento utilizando kits de medicamento.
MX2020001369A (es) Sistema de analisis para el cuidado de un paciente.
CL2019002084A1 (es) Herramienta para control de drogas.
MX387627B (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia
DK3160521T3 (da) Prøvetagningsanordning til bestemmelse af mængde og indgivet lægemiddeldosis og tilhørende fremgangsmåder
TN2014000498A1 (en) Pharmaceutical formulation
EP3372262A4 (en) MEDICAL LIQUID ADMINISTRATION DEVICE
EA201690537A1 (ru) Способы и средства для введения контрастной среды
EA201692432A1 (ru) Способ и устройство для определения времени распадаемости пленочной лекарственной формы
BR112017010721A2 (pt) seringa e método de identificação de uma dosagem precisa de medicamento em uma câmara de dosagem de uma seringa
EA202190596A3 (ru) Предоставление фармакокинетической схемы дозирования лекарственного средства
MX2017012449A (es) Tratamiento del dolor.
TH160649A (th) เครื่องและวิธีการสำหรับข้อกำหนดการให้ขนาดยาทางเภสัชจลนศาสตร์
UA82125U (ru) Способ прогнозирования рефрактур у больных с ложными суставами
MA38685A1 (fr) Fourniture d'un régime de dosage de médicament pharmacocinétique
UA106253U (ru) СПОСОБ ПРОГНОЗИРОВАНИЯ сращения перелома
UA96044U (ru) Способ прогнозирования сращивания перелома

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment